Simulations Plus (NASDAQ:SLP) Cut to “Buy” at BidaskClub

BidaskClub cut shares of Simulations Plus (NASDAQ:SLP) from a strong-buy rating to a buy rating in a research report released on Tuesday, BidAskClub reports.

A number of other research analysts have also recently weighed in on SLP. ValuEngine cut Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Zacks Investment Research cut Zynerba Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, May 11th.

Simulations Plus stock opened at $31.24 on Tuesday. The business’s fifty day moving average is $27.05. The stock has a market capitalization of $514.25 million, a P/E ratio of 66.73 and a beta of -0.38. Simulations Plus has a fifty-two week low of $16.70 and a fifty-two week high of $32.42.



Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Wednesday, July 10th. The technology company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.02. The company had revenue of $9.94 million during the quarter, compared to the consensus estimate of $9.85 million. Simulations Plus had a return on equity of 24.08% and a net margin of 24.09%. Equities research analysts forecast that Simulations Plus will post 0.44 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Thursday, July 25th will be given a dividend of $0.06 per share. The ex-dividend date is Wednesday, July 24th. This represents a $0.24 annualized dividend and a dividend yield of 0.77%. Simulations Plus’s dividend payout ratio is presently 48.00%.

In other Simulations Plus news, Director Walter S. Woltosz sold 18,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $25.67, for a total value of $474,895.00. Following the completion of the sale, the director now directly owns 5,178,083 shares in the company, valued at $132,921,390.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 31.57% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers lifted its stake in shares of Simulations Plus by 48.5% in the fourth quarter. Rhumbline Advisers now owns 15,309 shares of the technology company’s stock valued at $305,000 after buying an additional 5,000 shares in the last quarter. Royce & Associates LP raised its holdings in shares of Simulations Plus by 6,319.2% in the fourth quarter. Royce & Associates LP now owns 50,712 shares of the technology company’s stock valued at $1,009,000 after purchasing an additional 49,922 shares during the last quarter. Advisor Group Inc. increased its holdings in Simulations Plus by 156.9% during the fourth quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock worth $42,000 after buying an additional 1,290 shares during the last quarter. Bessemer Group Inc. increased its holdings in Simulations Plus by 8.6% during the fourth quarter. Bessemer Group Inc. now owns 31,700 shares of the technology company’s stock worth $631,000 after buying an additional 2,500 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Simulations Plus by 4.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 571,865 shares of the technology company’s stock worth $11,380,000 after buying an additional 25,871 shares during the last quarter. 41.28% of the stock is currently owned by institutional investors and hedge funds.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Read More: Capital Gains

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.